Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48Gastrointestinal Stromal Tumors 26Leukemia 20Leukemia, Myeloid, Chronic-Phase 15Philadelphia Chromosome 9Leukemia, Myeloid 8Bone Marrow Diseases 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Hematologic Neoplasms 4Hematologic Diseases 4Blast Crisis 4Myeloproliferative Disorders 3Leukemia, Myeloid, Acute 3Hypereosinophilic Syndrome 3Glioblastoma 3Digestive System Neoplasms 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Prostatic Neoplasms 2Neurofibrosarcoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Accelerated Phase 2Dermatofibrosarcoma 2Chordoma 2Brain Neoplasms 2Adenocarcinoma 2Urogenital Neoplasms 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × Imatinib Mesylate × Clear all
NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
15 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡